Cantor Fitzgerald Lowers MiMedx Group (NASDAQ:MDXG) Price Target to $8.00

MiMedx Group (NASDAQ:MDXG) had its price target decreased by investment analysts at Cantor Fitzgerald from $12.00 to $8.00 in a report released on Tuesday, MarketBeat Ratings reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 53.26% from the stock’s current price.

MDXG has been the subject of several other research reports. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Mizuho decreased their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Finally, Lake Street Capital reduced their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.33.

MiMedx Group Stock Up 1.2%

Shares of NASDAQ MDXG opened at $5.22 on Tuesday. MiMedx Group has a 1 year low of $4.89 and a 1 year high of $8.46. The firm’s 50-day moving average is $5.98 and its 200-day moving average is $6.67. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $773.08 million, a PE ratio of 19.33 and a beta of 1.59.

Hedge Funds Weigh In On MiMedx Group

A number of large investors have recently added to or reduced their stakes in MDXG. CWM LLC boosted its position in shares of MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after buying an additional 1,892 shares during the period. Legato Capital Management LLC lifted its stake in MiMedx Group by 18.5% in the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock valued at $121,000 after acquiring an additional 2,708 shares in the last quarter. HighMark Wealth Management LLC lifted its stake in MiMedx Group by 5.4% in the 3rd quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock valued at $390,000 after acquiring an additional 2,878 shares in the last quarter. SkyView Investment Advisors LLC boosted its position in MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after acquiring an additional 3,032 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its stake in shares of MiMedx Group by 4.6% during the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after acquiring an additional 3,064 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.